Amicus Therapeutics Ramps Up Gene Therapy Portfolio with Acquisition of 10 Programs

[cafead]

via

• Amicus will make an upfront cash payment of $100 million
• The company also announced closing a $150 million term loan to help finance the acquisition and development costs
• Lead programs are for three forms of Batten disease

article source